Utilization and clinical outcomes of sacubitril/valsartan in Sudanese heart failure patients: A multicenter cross-sectional study
Sacubitril/valsartan (Sac/Val) is a cornerstone therapy for heart failure with reduced ejection fraction (HFrEF), yet its real-world use remains poorly described in Sudan. This multicenter, cross-sectional study aimed to evaluate Sac/Val utilization patterns and clinical outcomes among 170 Sudanese...
Saved in:
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Pensoft Publishers
2025-06-01
|
| Series: | Pharmacia |
| Online Access: | https://pharmacia.pensoft.net/article/150398/download/pdf/ |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850132846357774336 |
|---|---|
| author | Alanood Elnaeem Mohamed Toga K. Mohamed Bashir A. Yousef Yaman Walid Kassab Kannan O. Ahmed |
| author_facet | Alanood Elnaeem Mohamed Toga K. Mohamed Bashir A. Yousef Yaman Walid Kassab Kannan O. Ahmed |
| author_sort | Alanood Elnaeem Mohamed |
| collection | DOAJ |
| description | Sacubitril/valsartan (Sac/Val) is a cornerstone therapy for heart failure with reduced ejection fraction (HFrEF), yet its real-world use remains poorly described in Sudan. This multicenter, cross-sectional study aimed to evaluate Sac/Val utilization patterns and clinical outcomes among 170 Sudanese patients. The mean patient age was 61 years, and 77.6% of patients found Sac/Val unaffordable. Additionally, 92.4% lacked insurance coverage. Most patients (62.4%) were de novo users, 78.8% initiated Sac/Val at 50 mg BID, 71.8% underwent up‑titration, and only 36.5% achieved the target dose of 200 mg BID. Notably, longer treatment duration was significantly associated with higher hospitalization rates (p = 0.003), while achieving the target dose correlated with improved ejection fraction (p = 0.045). Despite guideline-based initiation and titration, target dose achievement remains suboptimal. Socioeconomic barriers predominate, limiting treatment optimization. These findings highlight an urgent need for policymakers to integrate Sac/Val into national insurance programs and improve its affordability. |
| format | Article |
| id | doaj-art-8bfa61c9c8494c91bc2f069d77d5f2fa |
| institution | OA Journals |
| issn | 2603-557X |
| language | English |
| publishDate | 2025-06-01 |
| publisher | Pensoft Publishers |
| record_format | Article |
| series | Pharmacia |
| spelling | doaj-art-8bfa61c9c8494c91bc2f069d77d5f2fa2025-08-20T02:32:07ZengPensoft PublishersPharmacia2603-557X2025-06-01721710.3897/pharmacia.72.e150398150398Utilization and clinical outcomes of sacubitril/valsartan in Sudanese heart failure patients: A multicenter cross-sectional studyAlanood Elnaeem Mohamed0Toga K. Mohamed1Bashir A. Yousef2Yaman Walid Kassab3Kannan O. Ahmed4University of Medical Sciences and TechnologyUniversity of Medical Sciences and TechnologyUniversity of KhartoumNational University of Science and TechnologyNational University of Science and TechnologySacubitril/valsartan (Sac/Val) is a cornerstone therapy for heart failure with reduced ejection fraction (HFrEF), yet its real-world use remains poorly described in Sudan. This multicenter, cross-sectional study aimed to evaluate Sac/Val utilization patterns and clinical outcomes among 170 Sudanese patients. The mean patient age was 61 years, and 77.6% of patients found Sac/Val unaffordable. Additionally, 92.4% lacked insurance coverage. Most patients (62.4%) were de novo users, 78.8% initiated Sac/Val at 50 mg BID, 71.8% underwent up‑titration, and only 36.5% achieved the target dose of 200 mg BID. Notably, longer treatment duration was significantly associated with higher hospitalization rates (p = 0.003), while achieving the target dose correlated with improved ejection fraction (p = 0.045). Despite guideline-based initiation and titration, target dose achievement remains suboptimal. Socioeconomic barriers predominate, limiting treatment optimization. These findings highlight an urgent need for policymakers to integrate Sac/Val into national insurance programs and improve its affordability.https://pharmacia.pensoft.net/article/150398/download/pdf/ |
| spellingShingle | Alanood Elnaeem Mohamed Toga K. Mohamed Bashir A. Yousef Yaman Walid Kassab Kannan O. Ahmed Utilization and clinical outcomes of sacubitril/valsartan in Sudanese heart failure patients: A multicenter cross-sectional study Pharmacia |
| title | Utilization and clinical outcomes of sacubitril/valsartan in Sudanese heart failure patients: A multicenter cross-sectional study |
| title_full | Utilization and clinical outcomes of sacubitril/valsartan in Sudanese heart failure patients: A multicenter cross-sectional study |
| title_fullStr | Utilization and clinical outcomes of sacubitril/valsartan in Sudanese heart failure patients: A multicenter cross-sectional study |
| title_full_unstemmed | Utilization and clinical outcomes of sacubitril/valsartan in Sudanese heart failure patients: A multicenter cross-sectional study |
| title_short | Utilization and clinical outcomes of sacubitril/valsartan in Sudanese heart failure patients: A multicenter cross-sectional study |
| title_sort | utilization and clinical outcomes of sacubitril valsartan in sudanese heart failure patients a multicenter cross sectional study |
| url | https://pharmacia.pensoft.net/article/150398/download/pdf/ |
| work_keys_str_mv | AT alanoodelnaeemmohamed utilizationandclinicaloutcomesofsacubitrilvalsartaninsudaneseheartfailurepatientsamulticentercrosssectionalstudy AT togakmohamed utilizationandclinicaloutcomesofsacubitrilvalsartaninsudaneseheartfailurepatientsamulticentercrosssectionalstudy AT bashirayousef utilizationandclinicaloutcomesofsacubitrilvalsartaninsudaneseheartfailurepatientsamulticentercrosssectionalstudy AT yamanwalidkassab utilizationandclinicaloutcomesofsacubitrilvalsartaninsudaneseheartfailurepatientsamulticentercrosssectionalstudy AT kannanoahmed utilizationandclinicaloutcomesofsacubitrilvalsartaninsudaneseheartfailurepatientsamulticentercrosssectionalstudy |